Jun Zhang, MD, PhD
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (NCT05859217) | Jun Zhang, MD, PhD | 2024-12-01 |
| Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (NCT05332925) | Jun Zhang, MD, PhD | 2022-07-21 |
| Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (NCT04467801) | Jun Zhang, MD, PhD | 2021-09-14 |
| Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients (NCT04680377) | Jun Zhang, MD, PhD | 2021-04-12 |
| Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) (NCT04636775) | Jun Zhang, MD, PhD | 2020-07-29 |
Track Jun Zhang, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.